Editorial Volume 15, Issue 12 pp 5232—5234

Figure 1. Clinical benefit of new cancer drug indications approved by the FDA from 2003 to 2021. Notes: The waterfall plots visualize the clinical benefit of new cancer drug indications approved by the FDA between 2003 and 2021. Each blue bar represents the benefit of a single drug indication that was measured in the pivotal randomized controlled trial supporting the FDA approval. The red line indicates the median survival benefit. Graph (A) show the OS benefit and graph (B) the PFS benefit. In graph a, the outlier of midostaurin for acute myeloid leukemia with an OS benefit of 49.1 months was excluded for visualization purposes. Abbreviations: FDA, US Food and Drug Administration; OS, overall survival; PFS, progression-free survival.